News >

Combination Therapies Poised to Improve CLL Treatment Landscape

Danielle Bucco
Published: Monday, Jan 08, 2018

Aaron Logan, MD, PhD

Aaron Logan, MD, PhD
Combination regimens are generating excitement in the field of chronic lymphocytic leukemia (CLL), according to Aaron Logan, MD, PhD.

on Hematologic Malignancies, Logan, an assistant professor of clinical medicine, Division of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discussed the most promising combinations and available treatments for patients with CLL.

OncLive®: What is the current state of CLL?

Logan: CLL remains to be the most common leukemia in adults, representing about 25% of leukemia diagnoses. Due to its prevalence, there has been a lot of innovation in therapy for CLL, initially with combination monoclonal antibodies and cytotoxic agents called (chemoimmunotherapy). Those regimens have been standards of therapy for many years. We recognize that there are patients who have certain cytogenetic abnormalities, such as 17p deletion or abnormalities in p53, who did not benefit from those chemoimmunotherapy approaches. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication